Jing Wu1, Chaoyang Zhang2,3, Qian Yang4, Hai Xie4, Jingting Zhang2,3, Qinghua Qiu2,3, Kun Liu2,3, Dawei Luo2,3, Fang Liu1, Jingfa Zhang1,2,3,4. 1. Department of Ophthalmology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. 2. Department of Ophthalmology, Shanghai General Hospital (Shanghai First People's Hospital), Shanghai Jiao Tong University, Shanghai, China. 3. National Clinical Research Center for Eye Diseases, Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai Engineering Center for Precise Diagnosis and Treatment of Eye Diseases, Shanghai, China. 4. Tongji Eye Institute, Tongji University School of Medicine, Shanghai, China.
Abstract
PURPOSE: To investigate the hyperreflective foci (HRF) as an inflammatory biomarker using optical coherence tomography angiography (OCTA) in neovascular age-related macular degeneration (AMD) patients after antivascular endothelial growth factor (anti-VEGF) treatment and its association with the retinal microcapillary density. METHODS: Twenty-five eyes from 25 patients with neovascular AMD were included in the study. All eyes were imaged with OCTA at baseline (M0) and after 3 consecutive injections (M3; injection performed each month) of anti-VEGF. The number of HRF in the superficial capillary plexus (SCP), deep capillary plexus (DCP), and outer retina was counted. The vascular density of the fovea, parafovea, and the whole macula, as well as the area of the foveal avascular zone (FAZ), was measured. RESULTS: The mean interval between baseline and follow-up with OCTA was 93.08 ± 5.00 (range, 85-101) days. Compared with the baseline, the number of HRF significantly decreased in DCP (7.52 ± 3.06 vs. 3.76 ± 1.48, P < 0.01) and outer retina (12.04 ± 4.91 vs. 5.88 ± 3.32, P < 0.01) after treatment. There was no significant difference for HRF number in the SCP, the vascular density (containing foveal, parafoveal, and whole macular), and FAZ area before and after treatments. CONCLUSION: The number of HRF in DCP and outer retina might serve as an inflammatory biomarker in patients with neovascular AMD. The reduced HRF possibly represents the alleviation of inflammation after anti-VEGF treatment in patients with AMD.
PURPOSE: To investigate the hyperreflective foci (HRF) as an inflammatory biomarker using optical coherence tomography angiography (OCTA) in neovascular age-related macular degeneration (AMD) patients after antivascular endothelial growth factor (anti-VEGF) treatment and its association with the retinal microcapillary density. METHODS: Twenty-five eyes from 25 patients with neovascular AMD were included in the study. All eyes were imaged with OCTA at baseline (M0) and after 3 consecutive injections (M3; injection performed each month) of anti-VEGF. The number of HRF in the superficial capillary plexus (SCP), deep capillary plexus (DCP), and outer retina was counted. The vascular density of the fovea, parafovea, and the whole macula, as well as the area of the foveal avascular zone (FAZ), was measured. RESULTS: The mean interval between baseline and follow-up with OCTA was 93.08 ± 5.00 (range, 85-101) days. Compared with the baseline, the number of HRF significantly decreased in DCP (7.52 ± 3.06 vs. 3.76 ± 1.48, P < 0.01) and outer retina (12.04 ± 4.91 vs. 5.88 ± 3.32, P < 0.01) after treatment. There was no significant difference for HRF number in the SCP, the vascular density (containing foveal, parafoveal, and whole macular), and FAZ area before and after treatments. CONCLUSION: The number of HRF in DCP and outer retina might serve as an inflammatory biomarker in patients with neovascular AMD. The reduced HRF possibly represents the alleviation of inflammation after anti-VEGF treatment in patients with AMD.
Authors: Gabriel Coscas; Umberto De Benedetto; Florence Coscas; Concetta I Li Calzi; Sabrina Vismara; Françoise Roudot-Thoraval; Francesco Bandello; Eric Souied Journal: Ophthalmologica Date: 2012-09-19 Impact factor: 3.250
Authors: Francesco Romano; Alessandro Arrigo; Robert E MacLaren; Peter Charbel Issa; Johannes Birtel; Francesco Bandello; Maurizio Battaglia Parodi Journal: Retina Date: 2020-08 Impact factor: 4.256
Authors: Fiona Cunningham; Tine Van Bergen; Paul Canning; Imre Lengyel; Jean H M Feyen; Alan W Stitt Journal: Curr Eye Res Date: 2019-05-24 Impact factor: 2.424
Authors: Wan Ling Wong; Xinyi Su; Xiang Li; Chui Ming G Cheung; Ronald Klein; Ching-Yu Cheng; Tien Yin Wong Journal: Lancet Glob Health Date: 2014-01-03 Impact factor: 26.763
Authors: Tine Van Bergen; Isabelle Etienne; Fiona Cunningham; Lieve Moons; Reinier O Schlingemann; Jean H M Feyen; Alan W Stitt Journal: Prog Retin Eye Res Date: 2018-10-30 Impact factor: 21.198
Authors: Stefanie G Schuman; Anjum F Koreishi; Sina Farsiu; Sin-ho Jung; Joseph A Izatt; Cynthia A Toth Journal: Ophthalmology Date: 2009-01-22 Impact factor: 12.079
Authors: Matteo Stravalaci; Mariantonia Ferrara; Varun Pathak; Francesca Davi; Barbara Bottazzi; Alberto Mantovani; Reinhold J Medina; Mario R Romano; Antonio Inforzato Journal: Front Pharmacol Date: 2022-01-07 Impact factor: 5.810